A Warm Welcome to the 3rd Viral Vector Process Development & Manufacturing Summit!
Enhancing Scale-Up, Increasing Quality, & Reducing Costs for AVs, LVVs, AAVs & More
The 3rd Viral Vector Process Development & Manufacturing Summit returns to Boston, uniting industry leaders from the likes of Sanofi, Kite, Ultragenyx, Sangamo, UCB, and more to focus on advancing the production of viral vectors for cell and gene therapeutics.
2024 has been pivotal for viral vector manufacturing, with more gene therapies in market and regulatory frameworks evolving to support scalable production. With 800+ gene therapy candidates in clinical trials, the focus is on optimizing processes to reduce costs and improve consistency.
Don’t miss the only summit dedicated to viral vector process development and manufacturing, featuring talks, panels, roundtables, and 2 interactive workshops. Gain valuable insights into the regulatory landscape and data-driven presentations across upstream and downstream process development on key topics such as:
- Elevating Yield, Titer, and Potency
- Improving Capsid Ratios
- Advancing Purification Techniques
- Enhancing Scale-Up
- Seamless Tech Transfer
- Enhancing Vector Optimization
… and more!
“The event harbors an intimate space where experts are able to let down their guard and discuss latest technology, data, and ideas."
Alexandra Ortiz Rosa, Director, OyconBio, 2024 Attendee
World-Class Speaker Faculty Includes
Andrew Steinsapir
Director, Gene Therapy Program Lead | Acting Chief Technology Officer
Apertura Gene Therapy
“The 3rd Viral Vector Process Development & Manufacturing Summit features a thoughtful agenda focused on industry trends and new challenges. 2025’s invited speakers are also recognized as leaders in their respective fields.”
Ying Cai, Director, Ultragenyx, 2025 Speaker
Previously Attending Companies Include:
“This summit is a vital platform that brings together experts from diverse fields to address and solve pressing challenges in viral vector process development and manufacturing. The 2025 meeting will witness valuable discussions that will help drive innovation and advance solutions for optimizing viral vector production"
Yuanli Song, Associate Director, CMC Purification Process Development, Sanofi, 2025 Speaker
Download the Full Agenda for More Information on:
- 16+ Expert Speakers
- 2 Interactive Workshops
- 6+ Hours of Dedicated Networking Breaks
- 20+ Hours of Content
Our Partners
